10:21 AM EDT, 08/20/2024 (MT Newswires) -- Diagnos ( DGNOF ) , which operates in the field of early disease detection of the eye through its FLAIRE platform, was at last look up 10% after saying its quality management system now fully complies with ISO 13485 standard and applicable regulatory requirements for medical devices.

In order to commercialize its flagship product CARA, which is a picture archiving and communications system, DIAGNOS ( DGNOF ) must undergo statutory quality compliance audits under the Medical Device Single Audit Program (MDSAP), which streamlines regulatory audits across multiple countries. The company is working to obtaining regulatory licences in Canada and in the U.S. for four additional modules to assist health care professionals.

Diagnos ( DGNOF ) was up 10.5% to $0.37 on the TSX Venture Exchange.

Price: 0.37, Change: +0.04, Percent Change: +10.45